HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR)

HC Wainwright reissued their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR) in a research note released on Thursday morning, MarketBeat Ratings reports. HC Wainwright currently has a $40.00 price target on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2025 earnings at ($1.12) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.

OKUR has been the topic of several other reports. Oppenheimer began coverage on shares of OnKure Therapeutics in a report on Thursday, October 10th. They set an “outperform” rating and a $35.00 price target on the stock. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th.

OnKure Therapeutics Trading Down 3.4 %

NASDAQ:OKUR opened at $17.95 on Thursday. OnKure Therapeutics has a twelve month low of $9.80 and a twelve month high of $86.70. The stock has a market capitalization of $59.95 million, a P/E ratio of -1.07 and a beta of 0.21.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.